Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc Ord (OP: AZNCF )

158.14 +1.76 (+1.13%)
Streaming Delayed Price Updated: 3:29 PM EDT, Sep 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Astrazeneca Plc Ord

< Previous 1 2 3 4 5 6 7 8 Next >
Real-World Data In Canada Shows AstraZeneca's COVID-19 Jab Is Over 80% Effective Against Variants
Results from the Canadian Immunization Research Network (CIRN) showed that one dose of AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine was 82% effective... 
Via Benzinga
Exposures COVID-19
China Approves AstraZeneca's Imfinzi For Extensive-Stage Small Cell Lung Cancer
National Medical Products Administration of China has approved AstraZeneca plc's (NASDAQ: AZN) Imfinzi (durvalumab) to treat an aggressive type of lung cancer... 
Via Benzinga
India Made AstraZeneca's COVID-19 Vaccine Not Eligible For EU Travel, Seeks Resolution: Reuters
Serum Institute of India's (SII) CEO Adar Poonawalla said he was trying to resolve EU travel problems facing Indians inoculated with SII's licensed version of... 
Via Benzinga
Exposures COVID-19
AstraZeneca Kick-Starts New COVID-19 Variant Vaccine Trial
AstraZeneca Plc (NASDAQ: AZN) has started testing its new COVID vaccine, dubbed AZD2816, a tweaked version using the same platform as its authorized (though not in the... 
Via Benzinga
Exposures COVID-19
AstraZeneca's Nirsevimab Shows Favorable Safety, Tolerability Profile In Infants At High Risk Of RSV
AstraZeneca Plc (NASDAQ: AZN) announced data from the MEDLEY Phase 2/3 trial evaluating nirsevimab in infants at high risk of respiratory syncytial virus (RSV). The trial... 
Via Benzinga
AstraZeneca's Type 2 Diabetes Treatment Shows Clinical Benefit In Adolescents
AstraZeneca Plc (NASDAQ: AZN) has reported results from the Phase 3 trial evaluating exenatide extended-release 2mg in adolescents aged 10–17 years with type... 
Via Benzinga
AstraZeneca Unveils 5-Year Survival Data for Imfinzi in Lung Cancer Patients
AstraZeneca Plc’s (NASDAQ: AZN) has announced updated results from the PACIFIC Phase 3 trial of Imfinzi (durvalumab), showing survival benefit at five years... 
Via Benzinga
AstraZeneca Seeks Switching COVID-19 Vaccine Production to Catalent Plant: NYT
AstraZeneca Plc (NASDAQ: AZN) is in talks with the U.S. government to shift production of its COVID-19 vaccine from a troubled Emergent BioSolutions Inc’s (... 
Via Benzinga
Exposures COVID-19
AstraZeneca, Proteros Team Up To Develop Novel Anti-Cancer Medicines
Privately-held Proteros biostructures GmbH has signed an agreement with AstraZeneca Plc (NASDAQ: AZN) to jointly discover and develop novel small... 
Via Benzinga
AstraZeneca's Anifrolumab Shows Benefit In Skin, Joint Diseases In Systemic Lupus Erythematosus Patients
AstraZeneca Plc (NASDAQ: AZN) has announced a new posthoc analysis of pooled data from the TULIP Phase 3 clinical trials evaluating anifrolumab in patients with... 
Via Benzinga
AstraZeneca's Tagrisso Wins European Approval In Early Lung Cancer
AstraZeneca Plc’s (NASDAQ: AZN) top-selling Tagrisso drug has been approved for use in the European Union to treat patients with a type of early-stage lung... 
Via Benzinga
EU Seeks Fines For AstraZeneca Over COVID-19 Vaccine Delays: Reuters
The European Union took on AstraZeneca Plc (NASDAQ: AZN) in a Brussels court and accused it of diverting doses promised to the bloc to other nations. EU’s... 
Via Benzinga
Exposures COVID-19
Nipro To Provide Fill, Finish Services For AstraZeneca COVID-19 Shots In Japan: Reuters
Japan's Nipro Corporation has signed an agreement to supply AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine in Japan, reports Reuters. Nipro... 
Via Benzinga
Exposures COVID-19
New Five-Year Data Shows Durable Efficacy Of AstraZeneca's Fasenra For Asthma Treatment
AstraZeneca Plc (NASDAQ: AZN) has announced results from a new integrated analysis, including data from the MELTEMI Phase 3 open-label extension trial, evaluating... 
Via Benzinga
Oxford/AstraZeneca Third Booster Strong Enough Against COVID-19 Variants, Study Shows: FT
Oxford University and AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine works well as a third booster shot, according to a study, the Financial Times reported... 
Via Benzinga
Exposures COVID-19
AstraZeneca's Farxiga Flunks Late-Stage COVID-19 Study
AstraZeneca plc (NASDAQ: AZN) presented detailed data from the DARE-19 Phase 3 trial at the American College of Cardiology, evaluating Farxiga (dapagliflozin... 
Via Benzinga
Exposures COVID-19
UK Rethinks COVID-19 Antibody Supply Deal With AstraZeneca: Bloomberg
The U.K. government has reconsidered its plan to buy one million doses of AstraZeneca Plc’s (NASDAQ: AZN) anti-SARS-CoV-2 antibody, according to sources... 
Via Benzinga
Exposures COVID-19
AstraZeneca COVID-19 Vaccine Costs Hit Q1 Earnings; Cancer Meds, Emerging Markets Save The Day
AstraZeneca Plc (NASDAQ: AZN) generated $275 million in revenue from its non-profit COVID-19 vaccine in Q1. Still, it has not been able to keep up with its... 
Via Benzinga
Exposures COVID-19
I Got My Jab, Here's What Happened, And A Look At Vaccine Stocks
COVID-19 vaccine revenues and profits may be lowballed right now. Ultimately, the underlying companies have very strong business prospects independent of their COVID operations. 
Via Talk Markets
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.